Parnell Pharmaceuticals Holdings Ltd Announces First

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Parnell Pharmaceuticals Holdings Ltd Announces First Quarter Business Update

Parnell continues to grow rapidly with revenue increasing 43% for the three months ended March 31, 2016 OVERLAND PARK, Kan., April 22, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ: PARN ) , a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced business results for the first quarter of 2016 including strong revenue growth of 43%, the conclusion of negotiations on a contract manufacturing agreement with a major multi-national, the upcoming launch of two new products; Luminous ™ and Reviderm™ for the companion animal market and receipt of the US Food and Drug Administration, (FDA)’s responses for the two remaining Technical Sections for Zydax for dogs in the US.

“Parnell had a fantastic first quarter in 2016 with strong revenue growth across our whole business.  We were particularly pleased with our US Production business which performed above our expectations as did our Australian Companion Animal business.  Our US Companion team continued to establish a strong footprint in the market with Fetch™ (our digital app) and Glyde™ (our nutraceutical for osteoarthritis, or OA).  After several months of negotiations we have now agreed upon terms with a major multi-national pharmaceutical company on a contract manufacturing agreement that we expect to sign as early as next week.” said Robert Joseph, President and CEO of Parnell.

Mr. Joseph went on to say, “As we previously communicated to the market, we expected to receive a response this month from the FDA on our final two major Technical Sections for use of Zydax in dogs with OA.  When it comes to novel drug applications, the FDA almost invariably has clarifying questions in what is understandably a complex area for drug approvals.  The FDA has posed questions in relation to both our technical sections; we have had preliminary discussions with the FDA in relation to these and believe we will be able to provide the required data and adequate responses to the FDA’s questions.  We remain confident in our ability to file robust data packages and, based on our current expectations, aim to file our responses with the FDA in Q2, 2016. Meeting this response timeframe would keep us on track for a potential Zydax approval in late Q4, 2016.  After many years of hard work and innovation, we hope to be approaching the final stage on the path to approval for Zydax in the US.  We are equally as excited to be ramping up species and geographical expansion opportunities for Zydax; for example, we are in late negotiations for the appointment of a marketing partner for Zydax in Europe and negotiations have begun for other possible markets including Canada.  In 2016, we are embarking on Target Animal Safety and Effectiveness studies for the use of Zydax in Cats which we believe is a very valuable market.”

“We are also excited to confirm the pending launch of two new products in the US through our companion animal team.  Luminous™ is a novel nutraceutical product we have developed for use in dermatological conditions.  The dermatology market has seen recent rapid expansion with the introduction of novel pharmaceuticals and, just as we have seen the success of Glyde when used in conjunction with products like Zydax, we expect Luminous to appeal to dog owners who want their dogs to have healthy skin and shiny coats.  We are also proud to have recently in-licensed a novel liquid bandage product with strong antimicrobial properties called Reviderm™. The current standard of care for wounds is the adhesive bandage. Poor tolerance causes dogs to chew bandages which can lead to complications at the wound site.  We believe Reviderm offers a more elegant solution, combining antimicrobial properties that support wound healing and an impervious elasto-polymer that wears off naturally over time.  Both of these product introductions will further bolster our commercial offerings in the US and Australia and position Parnell as a growing player in the valuable Companion Animal market.” said Mr. Joseph.

Mr. Joseph went on to say, “Parnell has long been proud of the valuable sterile manufacturing facility we built and had approved by the FDA in 2013 and the European Medicines Agency, or EMA in 2015.  With 75% available capacity, we recently commenced negotiations with several major multi-nationals to contract manufacture sterile injectable products.  We have now concluded negotiations for one of these deals and expect to sign a contract as early as next week and commence manufacturing shortly thereafter.  We believe this deal will bring in millions of dollars of revenue over several years.  We also expect more deals to be concluded in the coming months thereby validating the multiple revenue generating opportunities Parnell’s business model provides.”

Unless otherwise specified, all amounts are presented in Australian Dollars (AUD).

Commercial Highlights

  • Total Company sales growth of 43% for Q1, 2016 over the same period in 2015 as we continued to grow in our Production Animal segments while expanding our Companion Animal business in the US & Australia;
    • Sales growth of 10% over the prior period in our U.S. Production Animal segment was driven by the continued success of our go-to-market strategy of clinical science leadership in the dairy reproduction segment and the continued roll-out mySYNCH®; our innovative digital technology that assists dairy farmers to improve the profitability of their operations. Most pleasing is that our “in-market sales” (sales from the distributor to producers and/or veterinarians) grew 51% as compared to Q1, 2015, demonstrating our continued strong performance in the US Production Animal segment.
    • Sales for Production Animal Rest-Of-World increased 83% in Q1, 2016 compared to the same period in 2015, primarily driven by year-over-year differences in the timing of orders from our marketing partners (outside Australia and New Zealand).
    • Our Companion Animal business segment continued to show increased sales growth in Q1, 2016 as a result of the expansion of our sales team and the launch of Glyde Chews and FETCH in the U.S.  Companion Animal Sales increased 164% compared to the same period in 2015.
  • Contract Manufacturing did not generate any revenue in Q1, 2016 but with the conclusion of negotiations on a contract manufacturing agreement we expect single digit millions in revenue to commence in Q2, 2016 and continue on an ongoing basis.
  • We reiterate our 2016 revenue guidance as previously stated in our 2015 Earnings Release dated February 24, 2016.

Development Highlights

  • We received the FDA’s response to our filings of the Target Animal Effectiveness Technical Section and the Chemistry and Manufacturing Controls Technical Section for Zydax.  The FDA’s Center for Veterinary Medicine has sought clarifications and responses in relation to various aspects of the filings.  Parnell has discussed the major areas of these questions with the FDA and believes that adequate responses can be prepared and submitted to the FDA within Q2, 2016.  This could lead to a potential approval in late Q4, 2016.
  • Parnell submitted a completed dossier for the approval of Zydax in dogs in the European Union in February, 2016.  This dossier was subsequently validated by the EMA review team and is now undergoing the assessment process proper.  Parnell expects to receive initial responses from the EMA in Q3, 2016.

Corporate Highlights

  • Continued negotiations with multiple parties to acquire the rights to market Zydax ® in Europe, with a deal expected to be completed in Q2, 2016.
  • Completed the in-licensing of Reviderm™, a novel antimicrobial liquid bandage for use on wounds in dogs, cats and horses.
  • Completed negotiations on a contract manufacturing agreement with a major multi-national and progressed several other contract manufacturing opportunities which may complete in Q2, 2016.
  • Completed a private placement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor ("Lincoln Park") to purchase 175,000 of our ordinary shares at $3.50 per share and 150,000 warrants to purchase our ordinary shares at a purchase price of $5.00 per share. In addition, in January, 2016 we entered into a separate share purchase agreement with Lincoln Park which is structured as an equity commitment and enables us to elect entirely at our discretion to sell up to 35,000 shares (and under certain circumstances up to 55,000 shares) on any one day to Lincoln Park.  Parnell commenced using this facility in small volumes in late March which appears to have contributed to an increase in daily share trading volume and thereby meeting our principal objective of entering into this agreement; to improve the liquidity of our stock trading.
  • Negotiated key terms for a senior debt facility of approximately $US30 million that is expected to complete, subject to final terms, in the coming month.
  • Appointed Will Hunsinger to our Board of Directors on April 20, 2016.  Mr. Hunsinger has been added to the Board based on his substantial experience in the technology industry, having previously been responsible for re-launching the e-commerce business for Gap, Banana Republic and Old Navy clothing retailers and then having worked with TPG Capital as an advisor and executive in various companies invested-in by TPG. Mr. Hunsinger also founded the social -mobile app company, SportStream which he successfully sold to Facebook Inc. Parnell is excited to have a technology executive of Mr. Hunsinger’s caliber and capability join the Board and his appointment underpins a strong focus on developing FETCH and mySYNCH ® as pivotal commercialization strategies.  

Operating Revenue Results (for the three month period ended March 31, 2016)

Total revenues increased by 43% for the three month period ended March 31, 2016, to $2.2 million, compared to the same period in 2015, with continued strong growth in our major markets. 

Our operating segments performed as follows: 

  • Production Animal – U.S.: Sales for the three months ended March 31, 2016 were $1.3 million, an increase of $0.1 million, or 10%, over the same period in 2015.
  • Production Animal – Rest of World (ROW): Revenues for the three month period ended March 31, 2016 increased by 83% to $0.3 million compared to the same period in 2015.
  • Companion Animal – Companion Animal product sales for the three months ended March 31, 2016 increased to $0.6 million, or 164%, compared to the same period in 2015.
  • We did not undertake contract manufacturing in Q1, 2016 or 2015.
  • As of March 31, 2016, cash and cash equivalents of $3.9 million compared to $5.7 million at December 31, 2015.  

Conference Call Information

Management will host a conference call on April 22, 2016 at 8:00 a.m. ET to discuss business performance for the first quarter.  Investors and analysts may access the conference call by dialing (877) 244-6184 (U.S./Canada) or (920) 663-6271 (International) and using the conference ID# 95345198.

A telephone replay will be available for one week following the call by dialing (855) 859-2056 (U.S./domestic) and (404) 537-3406 using the conference ID# 95345198. 

About Parnell

Parnell (PARN) is a fully integrated, veterinary pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. Parnell currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical products with proprietary digital technologies – FETCH™ and mySYNCH®. These innovative solutions are designed to enhance the quality of life and/or performance of animals and provide a differentiated value proposition to our customers.  Parnell also has a pipeline of 7 drug products covering valuable therapeutic areas in orthopedics, dermatology, anesthesiology, nutraceuticals and metabolic disorders for companion animals as well as reproduction and mastitis for cattle.

For more information on the company and its products, please visit www.parnell.com .

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words such as "may," "anticipate," "estimate," "expects," "projects," "intends," "plans," "develops," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. Forward-looking statements represent management's present judgment regarding future events and are subject to a number of risk and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding Parnell's research and development activities, its ability to conduct clinical trials of product candidates and the results of such trials, as well as risks and uncertainties relating to litigation, government regulation, economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on third parties, and other factors, including those described in Parnell's Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on March 4, 2016, along with its other reports filed with the SEC. In light of these assumptions, risks, and uncertainties, the results and events discussed in any forward-looking statements contained in this press release might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Parnell is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise. 

CONTACT: For more information, contact: Parnell Pharmaceuticals Holdings Robert Joseph, 913-274-2100 robert.joseph@parnell.com Brad McCarthy, 913-274-2100 brad.mccarthy@parnell.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 39

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
AMP Pushes Debt Wall to 2029 With €1.3B Green Notes

Updated Category News Views 25

A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...

Continue Reading
Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 158

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 75

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 64

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 32

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 23

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 17

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 72

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
Oman’s Dhofar II Wind Deal Clears Financing Hurdle

Updated Category News Views 111

Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...

Continue Reading

Top 5 Most Recently Viewed Articles

Settlement Reached for Just Energy Shareholders Amid Controversy

Updated Category News Views 341

Class Action Settlement Overview Recently, a significant settlement agreement was reached by representatives of former shareholders involved in a class action against Just Energy Group Inc. This move is part of the legal proceedings initiated after the company's restatement of its financial statements in 2019. Shareholders have been keenly watching the developments in...

Continue Reading
Texas Southern University Launches Impactful Lawson Endowment

Updated Category News Views 419

New Endowment Established by Texas Southern University Texas Southern University (TSU) is excited to unveil the creation of the William A. Lawson Endowment, a scholarship initiative that pays tribute to the remarkable legacy of Rev. Dr. William A. Lawson, a highly respected figure in the civil rights movement and a guiding light within the community. This endowment is...

Continue Reading
Thailand's Air Conditioner Market: Growth and Innovation Ahead

Updated Category News Views 544

Understanding the Growth Trends in Thailand's Air Conditioner Market Thailand has experienced a significant boost in its air conditioner market, projected to reach a valuation of over US$ 2,937.83 million by 2033, an increase from US$ 1,721.28 million in 2024. This growth translates to an impressive compound annual growth rate (CAGR) of 6.12% from 2025 to 2033. Several...

Continue Reading
BiomX Achieves Milestones and Reports Q2 2025 Financials

Updated Category News Views 204

BiomX Reports Second Quarter Financial Results BiomX Inc. (NYSE American: PHGE), a clinical-stage biotechnology company focused on developing innovative phage therapies, has shared its financial results and clinical updates for the second quarter of 2025, showcasing pivotal advancements that underscore its position within the industry. Positive Clinical Developments...

Continue Reading
Celebrating Community Heroes: The PuroClean Superhero Initiative

Updated Category News Views 217

PuroClean Honors Local Leaders with Superhero Day Campaign The Paramedics of Property Damage Celebrate Community Heroes Nationwide PuroClean, a renowned leader in restoration and remediation franchises, has recently concluded its captivating National Superhero Day campaign. This initiative celebrated everyday heroes across communities who have dramatically impacted lives....

Continue Reading